Board of Directors

The Board of Directors (BOD) provides strategic guidance and direction for Biological Dynamics' commercial operations. The BOD is comprised of renowned industry leaders from medical business, and venture arenas.  

Paul Billings, MD, PhD, FACP, FACMG - Chairman of the Board

Dr. Billings brings to Biological Dynamics extensive expertise in genomics and molecular medicine, as well as wealth of business, research, regulatory and health care experience.

Board certified internist and clinical geneticist, Dr. Paul R. Billings is an Executive-in-Residence at the California Innovation Center of Johnson & Johnson and the Medical Director of the IMPACT Cancer Care Program Thermo Fisher Scientific.

Dr. Billings has served on the Scientific Advisory Board of the FDA and the Genomic Medicine Advisory Committee at the U.S. Department of Veterans Affairs. He currently is a Director of the Personalized Medicine Coalition and a member of the IOM Genomics Roundtable at National Academy of Sciences.

During his work as the CMO of Life Technologies Inc. and then of the Genetic Sciences Division of TFS -  he focused on improving patient care through expanding the use of medically relevant genomic technologies in clinical settings. He has been a founder or CEO of companies involved in genetic and diagnostic medicine including GeneSage Inc., Omicia Inc., CELLective Dx Corporation and was Sr. VP for Corporate Development at LabCorp. He is currently a Board Director of Trovagene Inc. and CollabRX Inc.; he also serves on many other boards including the Council for Responsible Genetics, the country’s oldest independent biotechnology “watchdog” organization.

He is the author of nearly 200 publications and books on experimental and clinical medicine. His work on genetic discrimination was instrumental in the creation and passage of the federal Genetic Information Non-Discrimination Act of 2008.

Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in Immunology from Harvard University.

MORE INFORMATION: Wikipedia - Paul Billings

John L. "Kip" Miller

Mr. Miller is an accomplished executive with a proven track record of developing and growing global life science businesses, most notably at Life Technologies (now ThermoFisher Scientific) and BD Biosciences.

Until 2011, he served as President of the Genetic Systems at Life Technologies, an approximately $1B division of a market-leading provider of DNA sequencing systems developed for academic research, applied market segments for human identification, and clinical diagnostics. Prior to the formation of Life Technologies, Kip served as Senior Vice President of Invitrogen (2005-2008) where he led the $500M Biodiscovery division, a leading developer of life science tools and enabling technologies for biomedical research, pharmaceutical drug discovery services, and transplantation diagnostics. Earlier in his career Mr. Miller held a variety of responsibilities at BD Biosciences including General Manager and Vice President of Sales and Services of the Americas.

Mr. Miller is actively involved with early life sciences companies. He is a co-founder and active board member of Tonbo Biosciences, and an active board member at Solulink and Cellector Corporation. Mr. Miller also served on the board of Firefly Bioworks prior to its acquisition by Abcam in 2015.

Paul V Maier, MBA

Mr. Maier brings strong senior operational and financial experience, as well as an impressive track record of shaping and expanding life science businesses, to Biological Dynamics board.  He has over 25 years of experience as a senior executive in biotechnology and pharmaceutical companies, where he raised over $1.5 Billion in equity and debt financing and led a number of IPO and M&A transactions.
As Chief Financial Officer of Sequenom, Inc. from November 2009 through June 2014, Mr. Maier was instrumental in raising more than $360 million in equity and debt financing and commercializing Sequenom’s molecular diagnostics segment. He served as Chief Financial Officer at Ligand Pharmaceuticals Inc. from 1992 to 2007 where he helped build the venture-stage company into a commercial, integrated biopharmaceutical organization and ICN Pharmaceuticals (now Valeant Pharmaceuticals International, Inc.) where he served in various senior finance and general management roles.

Mr. Maier currently serves on the Board of Apricus Biosciences, International Stem Cell, MabVax Therapeutics, and Ritter Pharmaceuticals.  Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University.

Raj Krishnan, PhD - CEO

Dr. Raj Krishnan founded Biological Dynamics in 2010 with the mission to revolutionize the approach toward the diagnosis and treatment of high burden diseases- the manifestation of his long desire to help people with cancer and save lives. Receiving his Ph.D. in Bioengineering from UC San Diego, Raj moved to build a company based on the technology he developed for his dissertation, where he pioneered the use of AC Electrokinetics for the purpose of blood-based diagnosis.

For the last several years, under Raj's vision and guidance, Biological Dynamics has transformed from concept to early stage startup, and then to one of the most innovative diagnostic companies in Southern California. His passion and conviction has led BioDyn through 3 rounds of funding, securing over $30M in total. Raj has published several papers on AC Electrokinetics and was recently named to the Top 30 under 30 scientists by Forbes magazine.